08/09/2026 Imfinzi + Imdelltra demonstrated significant benefit in 1st‑line ES‑SCLC maintenance In registrational Phase 2 QUINTESSENTIAL trial, GPRC5D CAR T therapy (arlo‑cel) achieved significant ORR improvement in heavily pretreated multiple myeloma INBRX‑106 + pembrolizumab elicited strong ORR signal in Phase 2 part of Ph2/3 HexAgon-HN trial, driving expansion and FDA‑aligned path to Phase 3 confirmatory trial in HNSCC Imfinzi + Imdelltra demonstrated significant benefit i